Document is current

Article History

Received: 6 March 2025

Accepted: 6 May 2025

First Online: 2 June 2025

Declarations

:

: Eric L. Simpson has received personal fees from AbbVie, Amgen, Arcutis Biotherapeutics, Areteia Therapeutics, Boehringer Ingelheim, CorEvitas, Corvus Pharmaceuticals, Dermira, Eli Lilly, Evelo Biosciences, FIDE, Forte Biosciences, Galderma, GSK, Gilead Sciences, Impetus Healthcare, Incyte, Innovaderm Research, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, LEO Pharma, Merck, MJH holding (4/29/2021), Numab Therapeutics AG, Pfizer, Physicians World, Prime Pharma, Recludix Pharma, Regeneron, Roivant Sciences, Sanofi-Genzyme, Sitryx Therapeutics, Trevi Therapeutics, and Valeant. He has received grants from or serves as a principal investigator for AbbVie, Acrotech, Amgen, Arcutis Biotherapeutics, ASLAN, Castle Biosciences, CorEvitas, Dermavant, Dermira, Incyte, Kymab, Kyowa Kirin, LEO Pharma, Eli Lilly, Merck, National Jewish Health, Pfizer, Regeneron, Sanofi, TARGET-DERM, and VeriSkin. Jonathan I. Silverberg has served as an advisor, speaker, researcher, or consultant for AbbVie, Asana Biosciences, Dermavant, Galderma, GSK, Glenmark, Kiniksa, LEO Pharma, Lilly, Menlo, Novartis, Pfizer, Realm, and Sanofi/Regeneron. Vimal H. Prajapati has served as an advisor, consultant, and/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioJAMP/JAMP Pharma, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, Cipher, CorEvitas, Eczema Society of Canada, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, J&J Innovative Medicine, Janssen, Johnson & Johnson, LEO Pharma, Medexus, Novartis, Organon, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, UCB, and Valeant; has served as an investigator for AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Meiji Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Vyne Therapeutics; and has received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis, and Sanofi Genzyme. Kilian Eyerich has served as a consultant, scientific advisor for, and/or received research support from AbbVie, Almirall, Bristol Myers Squibb, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB. Norito Katoh has received honoraria as a speaker/consultant from AbbVie, Celgene Japan, Eli Lilly Japan, Jansen Pharma, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Sanofi, Taiho Pharmaceutical, and Torii Pharmaceutical; and has received grants as an investigator from AbbVie, A2 Healthcare, Boehringer Ingelheim Japan, Eisai, Eli Lilly Japan, Jansen Pharma, Kyowa Kirin, LEO Pharma, Maruho, Sun Pharma, Taiho Pharmaceutical, and Torii Pharmaceutical. Mark Boguniewicz has received research funds (grants paid to the institution) from Regeneron; has been an investigator for Incyte and Sanofi; and has served on advisory boards for AbbVie, Amgen, Dermavant, Eli Lilly, Glaxo, Janssen, LEO Pharma, Pfizer, Regeneron, and Sanofi Genzyme. Emma Guttman-Yassky is an employee of Mount Sinai; has received research funds (grants paid to the institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boehringer Ingelheim, Cara Therapeutics, Eli Lilly, Galderma, Glenmark/Ichnos Sciences, Innovaderm, Janssen, KAO, Kiniksa, Kyowa Kirin, LEO Pharma, Novan, Pfizer, Ralexar, Regeneron Pharmaceuticals, and UCB; and has received consulting fees from AbbVie, Almirall, Amgen, Arena, Asana Biosciences, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, LEO Pharma, Pandion Therapeutics, Pfizer, Ribon, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target PharmaSolutions, UCB, and Ventyx Biosciences. E. James Song has served as a speaker, consultant, or investigator for AbbVie, Alumis, Alphyn, Amgen, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, CorEvitas, Dermavant, DermBiont, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, MoonLake, Novartis, Pfizer, Sanofi & Regeneron, Sun Pharma, TARGET PharmaSolutions, TIMBER, and UCB. Wan-Ju Lee, Henrique D. Teixeira, Tianshuang Wu, Cristina Sancho Sanchez, Namita Vigna, and Brian M. Calimlim are full-time employees of AbbVie, and may hold AbbVie stock or stock options. Marjolein de Bruin-Weller has served as a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Amgen, Galderma, Aslan, Eli Lilly, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, and Takeda.

: As previously reported, Measure Up 1, Measure Up 2, and Heads Up were all conducted in accordance with Good Clinical Practice guidelines as defined by the International Conference on Harmonisation, the Declaration of Helsinki, and/or all applicable federal and local regulations [, ]. All three clinical trials were approved by the independent ethics committees or institutional review boards of the investigational centers, as appropriate. Further details regarding ethics approvals can be found in the primary publications for each study [, ]. All patients provided written informed consent before screening.